BioCryst Pharmaceuticals Inc R&D Day Transcript
Good afternoon, and welcome to the BioCryst Discovery Center of Excellence in Birmingham, Alabama. I'm John Bluth, the Chief Communications Officer at BioCryst, and we're so happy that some of you joined us here today, and a lot of you have joined us on the webcast to discuss our R&D Day portfolio.
We will be making some forward-looking statements today. So please review those. Those statements contain risks and you can find the details in our securities filings and on our website.
As you may have seen in the press releases we issued earlier today, we are going to be introducing you to 5 new programs today. And each and every one of them has the potential to be a first-in-class or best-in-class molecule, and we're going to take you through each of them in detail. We also announced today an exciting partnership with Clearside Biomedical that enables us to combine our plasma kallikrein inhibitor, avoralstat with Clearside's SCS Microinjector and device for patients with DME, and you're going to hear more
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
